Research Article

Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTERial Stiffness

Stephane Laurent1,2,†, Gilles Chatellier1,2,3, Michel Azizi1,2,4,5, David Calvet6,7, Gabriel Choukroun8,9, Nicolas Danchin1,2,10, Pascal Delsart11, Philippe Gousse12,13, Gerard London13, Jean-Jacques Mourad14, Bruno Pannier15, Helena Pereira1, Dominique Stephan15,16, Pierre Boutouyrie1,2,17, On Behalf of SPARTE Investigators†

1University of Paris, Paris, France
2Assistance-Publique Hopitaux de Paris, Georges Pompidou European Hospital, Paris, France
3Clinical Research Unit, INSERM, U970, Paris, France
4Hypertension Department and DMU CARTE, Paris, France
5INSERM, CIC1418, Paris, France
6Neurology Department, GHU Paris Psychiatrie Neurosciences, Sainte-Anne Hospital, Paris, France
7INSERM UMR 1266, FHU NeuroVasc, Paris, France
8Nephrology Dialysis Transplantation Department, CHU Amiens, France
9MP3CV Research Unit, University Picardie Jules Verne, France
10Cardiology Department, Georges Pompidou Hospital, Paris, France
11CHU Lille, Institut Cœur Poumon, Lille, France
12Service de Cardiologie/Hypertension Arterielle, Hospital Saint ANDRE, Centre Hospitalier Universitaire de Bordeaux, France
13Department of Nephrology, Manhes Hospital, Fleury Merogis, France
14Groupe Hospitalier Paris Saint-Joseph, Paris, France
15University of Strasbourg, Strasbourg, France
16UMR 1260, INSERM-Université de Strasbourg, Strasbourg, France
17Cardiovascular Research Center – PARCC, Paris, France

ARTICLE INFO
Article History
Received 26 May 2020
Accepted 04 July 2020

Keywords
Antihypertensive drugs
arterial stiffness
cardiovascular events
clinical trial
hypertension

ABSTRACT
Whether arterial stiffness is a surrogate end-point for cardiovascular and renal disease has never been directly demonstrated by a controlled clinical trial. Our main hypothesis is a better prevention of outcomes in high risk hypertensives with PWV normalization driven strategy than with usual blood pressure driven therapeutic strategy based on European Society of Hypertension-European Society of Cardiology (ESH–ESC) guidelines. The strategy for preventing cardiovascular and renal events based on arterial stiffness study is a multicenter open-label randomized controlled trial with blinded endpoint evaluation comparing a therapeutic strategy targeting the normalisation of Pulse Wave Velocity (PWV group) versus a classical therapeutic strategy only implementing the ESH–ESC Guidelines (conventional group), for reducing cardiovascular and renal events. Patients with primary hypertension, aged 55–75 years, and at medium-to-high cardiovascular risk will be included and followed-up for 4 years. In the PWV group, treatment will be adjusted to carotid-femoral PWV measured every 6 months. In the conventional group, PWV will be measured at baseline and every 2 years, but its value will be blinded to the investigator in charge of the patient. In the PWV group, the therapeutic strategy will preferably use a combination of Angiotensin-converting Enzyme Inhibitor (ACEI) [or Angiotensin Receptor Blockers (ARB)] and calcium channel blockers, as well as maximal recommended doses of ACEIs and ARBs. The primary combined endpoint includes stroke and coronary events (myocardial infarction, angioplasty, bypass), fatal or not, peripheral artery disease (angioplasty, bypass, amputation), hospitalization for heart failure, aortic dissection, chronic kidney disease (doubling of creatinine, dialysis), and sudden death. Twenty-five research centers will include a total of 1500 patients, in order to show a 20% reduction in the primary combined endpoint - the incidence of which is estimated at 10% per year - in the PWV group compared to the conventional group.

© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

1. INTRODUCTION
The treatment of hypertension is associated with the treatment of other Cardiovascular (CV) risk factors, in a “global risk” approach.

Hypertension Mediated Organ Damage (HMOD) increases CV risk, independently of Blood Pressure (BP) level. Although the treatment of hypertension aims at lowering BP to better reduce target organ damage and ultimately reduce CV and renal complications, very few studies have shown that a strategy aimed at reducing HMOD translates to reduction of CV and renal complications beyond BP reduction. Indeed, we know that for similar reduction in BP, the regression of HMOD differs markedly. This has been well demonstrated for the treatment-induced regression of Left Ventricular Hypertrophy (LVH) measured by either Electrocardiogram (ECG)
or echocardiography in the Losartan intervention for endpoint reduction in hypertension study (LIFE) [1–3], thus qualifying them as surrogate endpoints. However, results are less consistent regarding the translation of a treatment-induced reduction in urinary albumin excretion into a reduced incidence of CV events and slower progression of renal disease [4–6].

An exaggerated arterial stiffness, characterized by an elevated Carotid-femoral Pulse Wave Velocity (cPWV > 10 m/s) [7] can be considered as HMOD, here the organ being the aorta. The corrected 10 m/s threshold, that is also included in the 2013 European Society of Hypertension (ESH)/European Society of Cardiology (ESC) Guidelines for the management of hypertension [8], corresponds to the previous threshold of 12 m/s that figures in the 2007 ESH–ESC Guidelines [9], adjusted for carotid-femoral distance (coefficient 0.8) according to the 2012 international consensus [7]. However, aortic stiffness cannot qualify yet as such because no controlled study has shown until now that the reduction in arterial stiffness translates to reduction of CV and renal complication independently of BP reduction in hypertensive patients.

In order to be considered as a surrogate endpoint of CV events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values [10]. The repeated demonstration of the predictive value of arterial stiffness for CV events led to its inclusion in the 2013 and 2018 ESH/ESC Guidelines for the management of Hypertension [8,11], as HMOD. A position paper from the European Society of Cardiology - working group on peripheral circulation [12] scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary CV disease prevention. cPWV was one of the few biomarkers that fulfilled most of the criteria and, therefore, was close to being considered a clinical surrogate endpoint [12]. Finally, a recent call to action of the Lancet Commission on Hypertension [13] addressed the global burden of raised BP through a life-course strategy based on the quantification of early vascular ageing, an equivalent of arterial stiffness [14]. We thus set up the SPARTE trial as a Strategy for Preventing Cardiovascular and Renal Events based on ARTERial Stiffness. A detailed rational has been previously published [15].

In the SPARTE study, we hypothesized that a therapeutic strategy including the normalisation of arterial stiffness in addition to the implementation of international guidelines for normalisation of BP would reduce more CV and renal events compared to the unique implementation of the international guidelines for the management of hypertension. The objective of the present paper is to present the protocol in detail, to report the dates of the study and the inclusion dynamics, and discuss some feasibility elements.

Of note, the protocol has been submitted to ethical committee and funding institutions in 2012. Thus, 2007 ESH–ESC Guidelines for the management of hypertension [16] applied at that time. However, the references which appear in the present document in order to support the rational of the study, particularly those related to pharmacological treatment, have been updated.

2. MATERIALS AND METHODS

Strategy for preventing cardiovascular and renal events based on arterial stiffness is a multicenter study including 25 French clinical centers, among which 12 are Excellence Centers labelled by the ESH. It is investigator initiated and driven, funded by the French Ministry of Research (PHRC 2011- K110102 / N°ID RCB: 2012-A00023-40) and Fondation de Recherche sur l’Hypertension Arterielle (FRHTA). A list of the study sites is provided in Table S1.

2.1. Study Design

The trial is defined by the protocol NCT02617238 (http://www.clinicaltrials.gov/) as a multicentre randomised two parallel groups study using a prospective, randomised, open, blinded end-point design, aiming at comparing the efficacy of a therapeutic strategy targeting the normalisation of arterial stiffness for reducing CV and renal events (PWV group), in comparison with a classical therapeutic strategy implementing the ESH–ESC Guidelines [16] (conventional group), in patients with primary hypertension and medium-to-very high CV risk (Figure 1).

Since treatment of hypertension is adjusted on the repeated measures of PWV in the PWV group, SPARTE study is truly a "target driven, long-term intensified intervention trial".

- **Target driven study:** The target is not BP such as in ACCORD [17], CARDIO-SiS [18], JATOS [19] or UKPDS [20], but arterial stiffness. The target value of PWV is defined as 10 m/s, recommended by the 2012 "Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity" [7]. The value of 10 m/s is consistent with the median values of the 55–75 years categories, observed in the Reference Value - Arterial Stiffness Collaboration Study [21].

- **Long-term study:** Several studies have shown that long-term treatment is mandatory to reduce arterial stiffness independently of BP [22–25].

- **Intensified intervention trial:** A number of pharmacological studies have shown that such a BP-independent lowering of arterial stiffness has resulted in a slowing progression of renal disease [4–6].

| Experimental design of the SPARTE study. The SPARTE study is a 4 years multicentre randomised two parallel groups study using a PROBE design, aiming at comparing the efficacy of a therapeutic strategy targeting the normalisation of arterial stiffness for reducing cardiovascular and renal events (PWV group), in comparison with a classical therapeutic strategy implementing the ESH–ESC Guidelines (conventional group), in patients with primary hypertension and medium-to-very high CV risk. |

![Figure 1](image-url)
stiffness is best obtained using blockers of the renin–angiotensin–
aldosterone system, including high recommended doses of
Angiotensin-converting Enzyme Inhibitors (ACEI) [22,26] and
Angiotensin Receptor Blockers (ARB) [24,27] and when neces-
sary mineralocorticoid receptor blockers [28]. The therapeutic
strategy is detailed below.

2.2. Sample Selection

The coordinating center in Paris supplied the study documentation
to all participating centers. Study documentation has included a
description of the protocol and of the expected tasks, and the files
to be signed in relation to study participation agreement.

2.3. Screening and Randomization

Around 60 subjects were to be enrolled in each center upon verify-
ing the study eligibility criteria listed in Table 1.

Following a parallel group study design, eligible patients are ran-
domized one-to-one in the treatment arms. The randomization list,
created by the coordination center before the start of inclusions,
uses a randomized block design, and is stratified by center and
categories of CV risk. The randomization is centralized and made
available to centers through the web-based software CleanWeb
(Telemedicine Technologies, http://www.tentelemed.com/lasolu-
sion-cleanweb/). At randomization, the clinician obtains the patient
allocation group after having recorded the patient characteristics
required by the algorithm.

In each centre, one or more investigators are in charge of the
screening. After the initial visit and signature of the informed con-
sent, checking inclusion and exclusion criteria, the patients are
randomized. At inclusion visit, a clinical examination is performed
and the following elements will be recorded: Height, weight, waist
circumference; Systolic Blood Pressure (SBP), Diastolic Blood
Pressure (DBP) (three measurements with oscillometric device);
Risk factors (lipids, diabetes, hypertension, smoking); CV disease
history; Noncardiovascular disease history; HMOD; Biological
dosages (not more than 6 months before): creatinine and Estimated
Glomerular Filtration Rate (eGFR)-Modification of Diet in Renal
Disease (MDRD), blood glucose, total, HDL, LDL Cholesterol
(LDL-C), triglycerides, Na, K, albuminuria; Ongoing treatments
(pharmacological classes and doses).

Ambulatory Blood Pressure Monitoring (ABPM) is performed
immediately before the initial visit. Patients without treatment
who have normal BP at ABPM (24 h BP < 130/80 mmHg or day
BP < 135/85 mmHg) are not included in the study. In case ABPM is
not possible, Home Blood Pressure Monitoring (HBPM) is performed,
and patients with normal BP (<135/85 mmHg) are not included.

At baseline, the measurement of the PWV and central BP is done
immediately before or after the clinical workup. During the study,
in the PWV group, the value of PWV is made immediately avail-
able for the investigator. In order to improve the flow of patients
during the course of the study, this is the PWV measure closest to
the clinical visit that is used for adjusting treatment. In the conven-
tional group, the investigator in charge of the patient is blinded to
the value of the PWV. PWV is measured every 6 months for the
PWV group only. For the conventional group, PWV is measured at
baseline, 24 and 48 months (Figure 1). Whatever the group, in case
of early termination of the study for one patient, PWV is measured
at the time closest to the event, when possible within 15 days of
the event. Central BP and Augmentation Index (AIx) is measured
during each PWV measurement sessions, but results will not be
available to investigators of the PWV group who adjust treatment
on PWV only, and, by definition, to investigators of the conven-
tional group.

2.4. Pulse Wave Velocity and BP

Measurements

Carotid-femoral PWV is measured by applanation tonometry
using the Sphygmacor device (Atcor Medical, Sydney, Australia)
using the foot-to-foot method [7,29]. Briefly, the applanation probe
is positioned on the carotid artery, in order to record the carotid
pressure waveform [7,29]. Applanation is then performed immedi-
ately afterward on the common femoral artery. Pulse transit times
from concomitant ECG are calculated using the intersecting tan-
gent automatically calculated by the software. cfPWV is calculated
dividing travelled distance by the difference in transit times. For
calculating travelled distance, a coefficient of 0.8 is applied to the
direct (carotid-to-femoral) path length according to Van Bortel
et al. [7]. At least two PWV measurements are performed. If the
difference between the two measurements is more than 0.5 m/s, a
third measurement is taken and the median value is retained [7].

Central BP is measured by applanation tonometry using the
Sphygmacor device (Atcor Medical, Sydney, Australia) as described
previously and recommended [7,29,30]. Briefly, the applanation
probe is positioned on the radial artery (right arm), and optimal
applanation is obtained using visual inspection and following
built-in quality control indices. Radial waveforms are calibrated
using brachial SBP and DBP measured before and after applan-
ation (average). The central aortic waveform is calculated by
the device software using the generalized transfer function. BP values
are derived from the curve. AIx is measured, and AIx at heart rate
75 (AIx@75) is calculated through the software.

Brachial SBP and DBP and Heart Rate (HR) is measured using an
adapted cuff with any validated electronic oscillometric device, both
at the physician’s office during the outpatient clinic and at the tonom-
ometry center, according to ESH–ESC guidelines. Three measurements
are performed, and the average of measures 2 and 3 is retained.

Quality control is done before and during the study. All applanation
 tonometry centers are already experienced with arterial measure-
ments. They have all undergone training both at the Core Lab Facility
of Pharmacology Department in Pompidou Hospital and on site.
Centers are certified on the basis of five consecutive measurements
fulfilling pre-established quality features. All measurements are
centrally reviewed by the Core Lab immediately after having being
performed. A trained technician, blinded as to the center, period
and treatment, checks for quality of tracings and inconsistencies
in BP values. In the event of a mismatch, BP values could either
be corrected or measured again within 1 week. During the course
of the study, arterial measurements are randomly sent to the Core
Lab Facility of Pompidou Hospital, checked again, and appropriate
measures are to be taken to maintain a high level of quality.
### Table 1  SPARTE inclusion and exclusion criteria for enrolment

#### Inclusion criteria
- Age 55–75 years
- Male and female subjects
- Primary hypertension, treated or not, whatever the control of BP
- Treated for primary or secondary prevention (more than 6 months after stroke or MI, or stable angina or peripheral artery disease)
- Patients at medium-to-very high CV risk, i.e. satisfying either A, B or C conditions, according to the 2007 ESH–ESC Guidelines

**A. Grade 1 or 2 hypertension**

AND

- At least three CV risk factors according to ESH–ESC 2007 guidelines (see below)
- Or metabolic syndrome associating at least two of the following criteria, in addition to hypertension
  - HDL-C <1.0 mmol/L (0.4 g/L) (M) or <1.2 mmol/L (0.46 g/L) (F)
  - Triglycerides >1.7 mmol/L (>1.5 g/L)
  - Fasting blood glucose 5.6–6.9 mmol/L (1.02–1.25 g/L)
  - Waist circumference >102 cm (M) or 88 cm (F)

- Or type 2 diabetes
- Or target organ damage (see below)
- Or CV disease or chronic kidney disease
- Affiliation to social security
- Signed informed consent

**B. Grade 3 hypertension, i.e. SBP > 180 mmHg and/or DBP > 110 mmHg**

**C. ISH, i.e. SBP > 160 mmHg and DBP < 70 mmHg**

#### CV risk factors are:
- Age >55 years (H) or >65 years (F)
- Smoking
- Dyslipidemia, with total cholesterol > 5 mmol/L (1.9 g/L), LDL-C > 3 mmol/L (1.15 g/L), HDL-C <1.0 mmol/L (0.4 g/L) (H) and <1.2 mmol/L (0.46 g/L) (F), triglycerides > 1.7 mmol/L (>1.5 g/L)
- Fasting plasma glucose 5.6–6.9 mmol/L (1.02–1.25 g/L)
- Abdominal obesity defined as waist circumference >102 cm (H) or 88 cm (F)
- Family history of premature CV event [<55 years (H) or <65 years (F)]

#### Hypertension mediated organ damage

- ECG-LVH (Sokolow-Lyon > 38 mm or Cornell product > 2440 mm * ms)
- Echo LVH (LVMI ≥125 g/m² (H) or ≥110 g/m² (F))
- Intima-media thickness of the common carotid artery > 0.9 mm or plaque
- Aortic stiffness PWV > 10 m/s
- Ankle-brachial SBP index < 0.9
- eGFR <60 ml/min/1.73 m²
- Increase in serum creatinine >15 mg/L (M) or >14 mg/L (F)
- Microalbuminuria 30–300 mg/24 h or albumin/urinary creatinine ≥22 mg/g (M) or 31 mg/g (F)

#### Exclusion criteria

Cannot be included:
- Patients with normal ABPM or HBPM without treatment
- Patients with secondary hypertension
- Patients aged under 55 or over 75 years
- Low-risk CV patients
- Patients with severe chronic renal impairment [creatinine clearance (MDRD) < 30 ml/min/1.73 m²]
- Patients with type I diabetes
- Patients with severe disease threatening the vital prognosis in the short and medium terms
- Patients who previously experienced a painful gynecomastia under spironolactone
- Patients with alcohol dependence or excessive consumption of alcoholic beverages
- Patients with a history of neurovascular disease or coronary heart disease in the previous 3 months
- Patients with a history of acute or chronic heart failure (NYHA class III and IV)
- Patients with unstable angina
- AF less than 6 months
- Patients with aortic stent
- Patients with known aneurysms of the abdominal aorta
- Patients with atrioventricular block second or third degree without pacemaker
- Patients with severe chronic inflammatory disease
- Patients with severe chronic infectious disease
- Patients with progression of peripheral arterial disease
- Patients whose pregnancy is known or which has no effective contraception if she is of childbearing age, or if she is breastfeeding
- Patients who have expressed their opposition to participate in the protocol or have inability to understand or follow the protocol
- Patients living too far from the place of investigation
- Patients already participating in other drug research protocol

ISH, isolated systolic hypertension; LVMI, left ventricular mass index.
2.5. Duration of the Study

The follow-up study duration is 4 years, during which at least two visits are performed every year for each group (see Table 2 for detail). In the PWV group, one visit every 2 months is performed during the first 6 months in order to adjust treatments to PWV target of less than 10 m/s, and then every 6 months. In the conventional group, visits will occur at least twice a year (Figure 1).

At each of the follow-up visits, the following elements are recorded: Weight, height, waist circumference; Office SBP and DBP; Heart rate; Laboratory tests if required; Smoking; Ongoing treatments, including antihypertensive, lipid lowering, antiplatelet drugs; Clinical events: Stroke, coronary events, peripheral artery events, hospitalisation for heart failure, kidney events, and sudden death.

Ambulatory blood pressure monitoring (or HBPM if ABPM is not available) is performed at baseline, after 6 months and at the end of the study. The last visit is similar to the follow-up visits, except that PWV, ABPM (or HBPM if ABPM is not possible) and laboratory tests are systematically performed regardless of the group to which the patient belongs.

2.6. Blinding

Because SPARTE is an open-label study, blinding will apply for the endpoints in both groups (PWV group and conventional group). In the PWV group where PWV measurement is used to adjust the therapeutic strategy, both patients and investigators are aware of PWV values. In the control group, investigators and patients are blinded for PWV because PWV measurement is not used for adapting therapeutic strategy and only serves for comparing groups afterward.

All components of the primary outcomes of the study are adjudicated in a blinded fashion (allocation group and PWV value) by the Endpoint Adjudication Committee (EAC). The Clinical Research Unit (CRU) of Hopital Europeen Georges Pompidou (HEGP) in Paris serves as coordinating center and sends all outcome documents to each of the three EAC experts (D.C., G.C. and N.D.). In case of discrepancy, a face-to-face meeting or a teleconference is organised by the Paris CRU in order to reach a consensus. Only validated outcomes will enter the final data analysis.

2.7. Interventions

In the conventional group: no specific therapeutic strategy is done other than those included as mandatory in the ESH–ESC guidelines for the management of hypertension. The objective is to bring BP below 140/90 mmHg [16], targeting 130–139 mmHg for SBP and 80–85 mmHg for DBP [16]. These guidelines are followed not only for antihypertensive treatment but also for caring about other risk factors, in addition to other international guidelines.

In the PWV group, the objective is to bring PWV below the target of 10 m/s [7]. For that purpose, antihypertensive treatment is adjusted and CV risk factors corrected until normalisation of PWV. More specifically, in patients with controlled BP, the first goal is to normalise PWV. In patients with high BP, the first goal is to normalise BP, and then to adjust treatment for normalising PWV. Indeed, as discussed below, PWV can be reduced through both acute BP reduction (passive destiffening) and long-term BP reduction (arterial remodeling). In those patients, it is important to take into account the time delay between the normalisation of BP and that of PWV. This delay can reach several months [23]. Of note, the two goals (normalising BP or normalising PWV) could have overlapped since the therapeutic strategy used for normalising BP is also effective for normalising PWV beyond BP.

Therapeutic means to be used in the PWV group are detailed below in Table 3. The therapeutic strategy puts into application...
the results of several pharmacological studies comparing the efficacy of various pharmacological classes for lowering arterial stiffness independently of BP reduction. Several studies unequivocally showed that antihypertensive drugs are able to reduce arterial stiffness and/or wave reflections independently of the reduction in brachial BP, for instance after acute calcium channel blocker administration [31], after long-term ACE inhibition by perindopril [22] or trandolapril [26], and after long-term angiotensin-receptor blockade by valsartan [30] or olmesartan [25]. In addition, the antialdosterone drug spironolactone is able to reduce arterial stiffness beyond BP reduction [28]. Several reviews have concluded that Renin–Angiotensin System (RAS) blockers and Calcium Channel Blockers (CCB) are more potent than betablockers and diuretics for reducing arterial stiffness beyond BP reduction [24,32].

Combinations therapy using a RAS blocker (ACEI or ARB) and a CCB is recommended as first step, according to the 2007 ESH–ESC Guidelines for the management of hypertension [16], for a more effective control of BP. Regarding their effects on the arterial wall, the evidence originates mainly from studies on central BP. The following combinations have demonstrated their effectiveness for lowering central BP in the CAFE study [33] using the perindopril/amlodipine combination, the EXPLOR study using the valsartan/amlodipine combination [30], and the Japan-combined treatment with olmesartan and a calcium channel blocker versus olmesartan and diuretics randomized efficacy study (J-CORE) using the olmesartan/azelnidipine combination [34]. In the J-CORE study [34], the reduction in PWV was twice larger after olmesartan/azelnidipine than after olmesartan/hydrochlorothiazide. When a diuretic is indicated, indapamide should be preferred. This is based on the results of the preterax in regression of arterial stiffness in a controlled double-blind study (REASON), testing the effectiveness of the perindopril/indapamide combination on central SBP and PWV, compared to atenolol alone [35,36].

Beta-blockers are used as 4th line therapy, unless compelling indication. Each time betablockers are necessitated, a vasodilating one is used if no elective indication for a non-vasodilating beta-blocker exists (heart failure, atrial fibrillation, etc.). Vasodilating beta-blockers, such as nebivolol [37] or celiprolol [38,39], are preferred for their neutral or positive effect on central BP. Non-vasodilating beta-blockers, such as atenolol should be avoided, since this pharmacological class has shown deleterious effect on central BP, arterial stiffness [32,35], small artery remodeling [40], and left ventricular hypertrophy [41,42]. However, vasodilating beta-blockers are indicated only as 4th step, since a pro-fibrotic effect on the arterial wall cannot be excluded on the long term [39].

| Table 3 | Therapeutic strategy in the PWV group |
|---|---|
| **I. BP is controlled at entry** | |
| see II.b.2 | |
| **II. BP is not controlled at entry** | |
| **II.a. First step** | The first objective is to target a BP < 140 and < 90 mmHg, in the range 130–140 mmHg SBP and 80–85 mmHg. Combination therapy for all: |
| • favour ACEI (or ARB) + CCB | |
| • but also Diuretic (DIU) + ACEI or DIU + ARB or DIU + CCB | |
| • avoid beta-blocker | |
| • no ACEI + ARB combination | |
| **II.b. Second step** | |
| **II.b.1. Either BP remains not controlled** | Use a triple combination: DIU + ACEI (or ARB) + CCB And then, if BP is still not controlled or side effects occur, as third step: |
| • go to the highest recommended doses of ACEI (ex. perindopril 10 mg) or ARB (irbesartan 300 mg), within the combination | |
| • and/or add a vasodilating beta-blocker (if no compelling indication for a non VD-BB): celiprolol 200 mg or nebivolol 5 mg | |
| • and/or increase the dose of HCTZ to 25 mg/day or preferentially indapamide PR up to 1.5 mg | |
| **II.b.2. Or BP is controlled but PWV is not reduced/normalised** | |
| • Take into account the time delay between previous modifications of treatment and the BP-independent reduction in PWV | |
| • Check with ABPM/HBPM that there is no masked hypertension | |
| • Check that a combination therapy has been prescribed: | |
| • favour ACEI (or ARB) + CCB | |
| • but also DIU + ACEI or DIU + ARB or DIU + CCB | |
| • avoid beta-blocker | |
| • no ACEI + ARB combination | |
| • If at least 3 months have passed since the last intensification of treatment and if there is no masked hypertension, go to the highest recommended doses of ACEI (ex. perindopril 10 mg) or ARB (ex. irbesartan 300 mg) within the combination | |
| • And then, if PWV is still not significantly reduced | |
| • as step 3, increase the dose of HCTZ up to 25 mg/day or, preferentially indapamide PR up to 1.5 mg | |
| • and then, as step 4: according to kaliemia: either add a vasodilating beta-blocker (if no compelling indication for a non VD-BB): celiprolol 200 mg or nebivolol 5 mg; or add spironolactone 12.5 mg then 25 mg | |
| • and then, as step 5: add a loop DIU, or an alpha-blocker, or rilmenidine | |
| **Anytime, if BP is too low, go back one or more steps** | |

HCTZ, hydrochlorothiazide.
Spironolactone is used as an alternative to BB as 4th line therapy.

Anytime, in case of poor treatment tolerance (for instance if BP is too low, or adverse reaction, or orthostatic hypotension), a step down is authorized.

Other CV risk factors are corrected according to international guidelines, in particular:

- smoking cessation, associated if necessary, by support for smoking cessation
- limited salt intake (NaCl) up to 6 g/day
- weight reduction in overweight patients, to maintain BMI (body mass index) below 25 kg/m², or, failing that, to achieve a 10% reduction of the initial weight
- regular physical activity, tailored to the patient’s clinical condition, at least about 30 min three times a week
- limited alcohol intake to less than three glasses of wine or equivalent per day in men and two glasses of wine or equivalent per day for women;
- diet rich in vegetables, fruits and low in saturated fat (animal fat).

Oral antidiabetic agents, lipid lowering agents and antiplatelet agents are used as recommended by international guidelines.

2.8. Outcomes

2.8.1. Primary endpoint

The primary endpoint is a combined endpoint including first CV events, fatal or not: Stroke, coronary event [Myocardial Infarction (MI), angioplasty, bypass], Peripheral Artery Disease (PAD) (angioplasty, bypass, amputation), hospitalization for heart failure, aortic dissection, Chronic Kidney Disease (CKD) (doubling of creatinine, dialysis), sudden death. Patients who have presented an event are followed according to the methods recommended by learned societies and/or the French Ministry of Health guidelines. Recurring events are recorded and validated by an independent committee. On purpose, are not included Transient Ischemic Attack (TIA) and new onset of atrial fibrillation.

2.8.2. Secondary endpoints

- “Restricted” combined endpoint, including fatal CV events and non-fatal MI and stroke.
- All individual components included in the combined endpoint are analysed separately: stroke, coronary event (MI, angioplasty, bypass), PAD (angioplasty, bypass, amputation), hospitalization for heart failure, aortic dissection, CKD (doubling of creatinine, dialysis), sudden death.
- Percentage of normalization of the PWV at the end of study in each group.
- Values of PWV, central BP [SBP and Pulse Pressure (PP)] and AIx at the end of study.

- Time-course changes in brachial BP (SBP, DBP, mean blood pressure (MBP) and PP) measured at office, at home, and during PWV measurement sessions; in central SBP, PP and AIx; in PWV; in Ambulatory BP (24 h, day, and night SBP and DBP); and in biological parameters (particularly GFR estimated by MDRD).
- Time-course changes in the risk of fatal cardiovascular events (annually evaluated by the European Systematic CORonary Risk Evaluation [SCORE]) [43] and “fatal + non-fatal” events (estimated by the Framingham equation) [44].
- Time-course changes in treatments, in terms of pharmacological classes and doses (estimated as low, medium and high).

All clinical events are judged by an independent EAC blinded to the group. Clinical endpoints are prespecified with a detailed description in order to help physicians to report endpoints and to allow experts of the EAC to confirm or rule out diagnosis. The first qualifying event is used for morbidity and mortality analysis. Each of the events of the combined endpoint are validated by the EAC. The values of PWV, central BP, brachial BP, ABPM and HBPM are established as set out in the Protocol. It is the same for biological values, European scores (SCORE) and Framingham risk scores.

2.9. Sample Size and Power Consideration

The sample size calculation has been performed using nQuery Advisor* 5.0 (Statistical Solutions, Saugus, MA, USA). A proportion test was used as an approximate estimation for the sample size calculation (two-sided Z-test with unpooled variance). The sample size of the study has been calculated from the main criteria (combined endpoint): stroke + coronary events (MI, angioplasty, bypass) + PAD (angioplasty, bypass, amputation) + hospitalization from congestive heart failure + aortic dissection + doubling plasma creatinine + end stage renal disease + sudden death.

Considering a yearly incidence of the combined endpoint of 10% per year, a 20% risk reduction by the therapeutic strategy targeting PWV, a 4-year follow-up period and an alpha risk of 5%, a sample size of 1500 patients per group gave a power high enough for analysing both the combined endpoint and the “restricted” combined endpoint including fatal and non-fatal MI and strokes. A detailed explanation is given below.

According to the Cardio-Sis [18], ACCORD [17], and STENO [45,46] studies, one can reasonably estimate an incidence of composite events in the SPARTE study of about 10% per year, and their reduction through targeted strategy on PWV 20%. On this basis, we calculated the following estimates after a 4-year follow-up period. A sample size of 1500 patients per group gave a power high enough for analysing both the combined primary endpoint and an acceptable power (70%) for the “restricted” endpoint (fatal and non-fatal stroke or MI), thus allowing performing a subgroup analysis with a reasonable power (Table 4).

2.10. Data Collection

The study uses an Electronic Case Report Forms [eCRF (CleanWeb, Telemedicine Technologies)]. All information required by the
Table 4 Prediction of primary endpoint

| N patients | N events control | N events intervention | Difference | Power | Alpha |
|------------|-----------------|-----------------------|------------|-------|-------|
| 250        | 100             | 80                    | 20         | 0.46  | 0.05  |
| 500        | 200             | 160                   | 40         | 0.75  | 0.05  |
| 750        | 300             | 240                   | 60         | 0.9   | 0.05  |
| 1000       | 400             | 320                   | 80         | 0.96  | 0.05  |
| 1250       | 500             | 400                   | 100        | 0.98  | 0.05  |
| 1500       | 600             | 480                   | 120        | 0.99  | 0.05  |

Prediction of fatal CV events and non-fatal MI and stroke

- 250: 40 - 32 = 8, Power = 0.17, Alpha = 0.05
- 500: 80 - 64 = 16, Power = 0.30, Alpha = 0.05
- 750: 120 - 96 = 24, Power = 0.42, Alpha = 0.05
- 1000: 160 - 128 = 32, Power = 0.53, Alpha = 0.05
- 1250: 200 - 160 = 40, Power = 0.62, Alpha = 0.05
- 1500: 240 - 192 = 48, Power = 0.70, Alpha = 0.05

2.13. Ethical Considerations

The SPARTE study protocol has initially received approval by the Ethics Committee central pulse pressure (CPP) of Ile-de-France XI, on June 14th 2012, that is applicable to all participating centers. This is an investigator generated and driven study and as such is performed in full independence of the study sponsors, i.e. “Assistance Publique-Hôpitaux de Paris, Direction de la Recherche Clinique et du Développement”, and “FRHTA”.

According to the bioethics laws, the investigator has the obligation to inform the patients before their recruitment for clinical research studies, even if these studies are common clinical care. In accordance with the local rules, the information of patients participating to research is ensured with a written document previously validated by the Ethics committee. The investigator from the center offers the patient to participate in the study, orally informs him/her about the modalities of the study and deliver him/her the information note. The investigator mentions the “non-opposition” in the patient's medical record in case of acceptance to participate. In case of refusal, this information will also be mentioned there (and the patient will not be included). When the study is completed, the participating patient may be informed of the overall results of this research in a manner that is specified in the information document.

According to the French bioethics law, there is no need of informed consent here because the SPARTE protocol is aiming at evaluating usual clinical care, by comparing two therapeutic approaches using therapeutic means and drugs already recommended by national or international guidelines, without added risk and with few constraints. Indeed, the algorithm for intensifying anti-hypertensive treatment in the PWV group is in accordance with the French guidelines, issued by the French Ministry of Health, Haute Autorité de Santé [48]. An informed consent would have been required if, for instance, the protocol would have included a novel drug.

2.14. Progress of the Study

The first patient was included on July 26, 2013. The last patient last visit occurred on January 26, 2020. The inclusion rate and consequently the total number of patients were lower than expected because of competing protocols in several centers. The protocol is currently being replicated in Poland (Prof. Krzysztof Narkiewicz, Gdansk University) and in Portugal (Prof. Pedro Cunha, Guimaraes-Minho University).
CONFLICTS OF INTEREST

S.L. has received honoraria as lecturer for Menarini, Sanofi and Servier, and Axelife, Omron and Withings. G.C. none. M.A. has received research grants from the French Ministry of Health, Quantum genomics and European H2020 program; has received grant support and non-financial support from ReCor Medical and Idorsia; and has received personal fees from CVRx. D.C. none. G.C. has received honoraria as lecturer, participant to board of experts, and travel grants from Astellas, Sanofi, ViFor Pharma, and Amgen. N.D., P.D., P.G. and G.L. none. J.J.M. has received honoraria for consultancy or lectures for Mylan, Pfizer and Servier. B.P. and H.P. none. D.S. has received honoraria as lecturer for Servier. P.B. currently serves as President of ARTERY sponsored by an unconditional grant by SERVIER.

AUTHORS’ CONTRIBUTION

SL, GC, MA, GL, JJM, BP and PB contributed to the conception and design of the study. SL, GC and PB drafted and wrote the protocol in accordance to the coauthors’ contributions. All authors contributed to the writing and the reviewing of this article, and approved the final draft of the protocol.

FUNDING

French Ministry of Research (PHRC 2011- K110102 / N°ID RCB: 2012-A00023-40) and Fondation de Recherche sur l‘Hypertension Arterielle (FRHTA). Centers received funding from the Ministry of Research in proportion to the number of patients included in the study, which was paid directly to the hospital and targeted to the salary of a clinical research technician. Centers were also allocated a Sphygmocor device (Atcor Medical, Sydney, Australia) from FRHTA.

ACKNOWLEDGMENTS

The names of the collaborating centers and investigators of the SPARTE Study are listed in Supplementary file. Chantal Andrieux (CRU of Georges Pompidou Hospital) acted as clinical study manager from 2013 to 2019.

ABBREVIATIONS

ABPM, ambulatory blood pressure monitoring; ACEI, angiotensin converting enzyme inhibitor; AP-HP, Assistance Publique – Hôpitaux de Paris; ARB, angiotensin receptor blockers; BP, blood pressure; CCB, calcium channel blockers; CKD, chronic kidney disease; CRF, case report form; CRU, clinical research unit; CV, cardiovascular; DBP, diastolic BP; EAC, Endpoint Adjudication Committee; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HBPM, home blood pressure monitoring; HEGP, Hospital Europeen Georges Pompidou; HMOD, hypertension mediated organ damage; HT, hypertension; LVH, left ventricular hypertrophy; MDRD, modification of diet in renal disease; MI, myocardial infarction; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic BP; TIA, transient ischemic attack.

PATIENT CONSENT

Not required. However, patients should express that they are not opposed to participate to the protocol.

SUPPLEMENTARY MATERIAL

Supplementary data related to this article can be found at https://doi.org/10.2991/artres.k.200711.001.

REFERENCES

[1] Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetroiu V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350–6.
[2] Bang CN, Devereux RB, Okin PM. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction – a LIFE review. J Electrocardiol 2014;47:630–5.
[3] Gosse P, Cremer A, Viroulou M, Coulou P, Jan E, Papaoannou G, et al. Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. J Hypertens 2012;30:2403–9.
[4] Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198–202.
[5] Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011;32:1493–9.
[6] Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 2014;64:74–85.
[7] Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445–8.
[8] Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281–357.
[9] Mancia G, De Backer G, Cifkova R, Dominiczak A, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.
[10] Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408–16.
[11] Williams B, Mancia G, Spiering W, Agabiti-Rosei E, Azizi M, Burnier M, et al. 2018 ESC/EAS Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–104.

[12] Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cifkova R, Cosentino F, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis 2015;241:507–32.

[13] Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifestyle strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016;388:2665–72.

[14] Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009;54:3–10.

[15] Laurent S, Briet M, Boutouyrie P. Arterial stiffness as surrogate endpoint: needed clinical trials. Hypertension 2012;60:518–22.

[16] Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536.

[17] ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–85.

[18] Verdecchia P, Staessen JA, Angeli F, de Simone G, Achiili A, Ganaa A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525–33.

[19] JATOS Study Group. Principal results of the Scandinavian trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115–27.

[20] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.

[21] The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 2010;31:2338–50.

[22] Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balskestein E, Katsahian S, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006;48:80–6.

[23] Ait-Oufella H, Collin C, Bozec E, Laloux B, Ong KT, Dufouil C, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens 2010;28:2336–41.

[24] Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011;29:1034–42.

[25] Laurent S, Boutouyrie P. Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension 2014;64:709–16.

[26] Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JMO, Tardif JC, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007;49:1271–7.

[27] Boutouyrie P, Beaussier H, Achouba A, Laurent S, EXPLOR Trialists. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hypertens 2014;32:108–14.

[28] Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. J Am Coll Cardiol 2009;54:505–12.

[29] Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588–605.

[30] Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010;55:1314–22.

[31] Stefanidis C, Derellis J, Vlachopoulos C, Tsioufis C, Tsiamis E, Toutouzas K, et al. Aortic function in arterial hypertension determined by pressure-diameter relation: effects of diltiazem. Circulation 1997;96:1853–8.

[32] Boutouyrie P, Lacolley P, Briet M, Reignault V, Stanton A, Laurent S, et al. Pharmacological modulation of arterial stiffness. Drugs 2011;71:1689–701.

[33] Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–25.

[34] Matsui Y, Eguchi K, O’Rourke MF, Ishikawa J, Miyashita H, Shimada K, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009;54:716–23.

[35] Asmar RG, London GM, O’Rourke ME, Safar ME, REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922–6.

[36] London GM, Asmar RG, O’Rourke MF, Safar ME, REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92–9.

[37] Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351–6.

[38] Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B, et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000;101:2601–6.
[39] Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476–84.

[40] Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009;27:1107–14.

[41] Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507–13.

[42] Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084–91.

[43] Conroy RM, Pyörälä K, Fitzgerald AP, Sams S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.

[44] Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47.

[45] Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.

[46] Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91.

[47] Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

[48] HAS. Haute Autorité de Santé. Prise en charge des patients adultes atteints d’hypertension artérielle essentielle. Actualisation 2005. Argumentaire. HAS/Service des recommandations professionnelles/Juillet 2005. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2011-09/hta_2005_-_argumentaire.pdf.